Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads.
Biopharmaceutical science is accelerating at a record pace, leading to new discoveries that are radically reshaping our ability to fight disease. At the same time, politicians in Washington, D.C., are considering legislation to lower drug costs this week that threatens this progress and would put us on a path to government-run health care.
As president and CEO of PhRMA, I recently got a chance to meet with scientists and tour the labs at several biopharmaceutical companies that are pioneering research in cell and gene therapies, two of the most promising areas of scientific research.
